How have BNGO and ESLA total returns compared?

Over the past 5 years, BNGO delivered -78.37% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.

Bionano Genomics, Inc. (BNGO) vs Estrella Immunopharma, Inc. (ESLA)

A side-by-side comparison of Bionano Genomics, Inc. and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BNGO

Bionano Genomics, Inc.

$17M

$1.45HealthcareDelayed quote: Oct 6, 2026, 3:39 PM EDT

ESLA

Estrella Immunopharma, Inc.

$18M

$0.43HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT

Total return — BNGO vs ESLA

growth of $100 · dividends reinvested · last 5y

BNGO -100.0% (-78.5%/yr)ESLA -95.5% (-46.2%/yr)ESLA compounded faster over this window

Log scale — wide-divergence pair

BNGO ESLA

BNGO vs ESLA: by the numbers

•ESLA is the larger company ($18M vs $17M market cap).
•Both run net losses; ESLA's is the smaller (0.00% vs -106.58% net margin).

Metrics side by side

Valuation

Metric	BNGO	ESLA
P/S ratio	0.55	N/A
P/B ratio	0.52	N/A

Profitability

Metric	BNGO	ESLA
Gross margin	21.95%	0.00%
Operating margin	-116.95%	0.00%
Net margin	-106.58%	0.00%
ROE	-101.76%	N/A
ROIC	-85.72%	N/A

Growth (annualized)

Metric	BNGO	ESLA
Revenue CAGR (5Y)	17.97%	N/A
Total return CAGR (5Y)	-78.37%	-46.34%

Frequently asked

How have BNGO and ESLA total returns compared?: Over the past 5 years, BNGO delivered -78.37% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BNGO analysis Full ESLA analysis Interactive comparison tool

Dig into the metrics

Bionano Genomics ROE Estrella Immunopharma ROE Bionano Genomics operating margin Estrella Immunopharma operating margin Bionano Genomics revenue growth Estrella Immunopharma revenue growth Bionano Genomics free cash flow Estrella Immunopharma free cash flow

Bionano Genomics & Estrella Immunopharma appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.